tiprankstipranks
Trending News
More News >
Revelation Biosciences (REVB)
NASDAQ:REVB
US Market

Revelation Biosciences (REVB) AI Stock Analysis

Compare
184 Followers

Top Page

RE

Revelation Biosciences

(NASDAQ:REVB)

Rating:28Underperform
Price Target:
Revelation Biosciences is heavily challenged financially with no revenue and persistent losses. Technical indicators suggest bearish momentum, while valuation metrics reflect severe investor concerns, particularly due to the negative P/E ratio. The company's reliance on external financing due to negative cash flows adds to the risk profile.

Revelation Biosciences (REVB) vs. SPDR S&P 500 ETF (SPY)

Revelation Biosciences Business Overview & Revenue Model

Company DescriptionRevelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
How the Company Makes MoneyRevelation Biosciences generates revenue primarily through the development and commercialization of its therapeutic candidates. The company's revenue model may include research and development collaborations, licensing agreements, and potential future product sales. Key revenue streams likely involve partnerships with larger pharmaceutical companies for joint development or commercialization efforts, as well as securing funding through grants or investments to support ongoing research. Currently, as a clinical-stage company, significant earnings may not be realized until products receive regulatory approval and reach the market.

Revelation Biosciences Financial Statement Overview

Summary
Revelation Biosciences faces significant financial challenges with no revenue generation and persistent losses. While the balance sheet is not burdened by debt, the dependence on external financing raises concerns about future liquidity. The ongoing negative cash flow highlights the urgent need for strategic changes to improve financial health.
Income Statement
5
Very Negative
Revelation Biosciences has no revenue over the reported periods, which is concerning for any growth trajectory. The company consistently reports negative EBIT and net income, indicating ongoing losses with no apparent path to profitability. The absence of revenue growth and negative margins are significant weaknesses.
Balance Sheet
30
Negative
The balance sheet shows a relatively strong equity position with no debt, which reduces financial risk. However, the company has negative net income, impacting the return on equity. The equity ratio is reasonable but challenged by the continual losses and lack of revenue generation.
Cash Flow
20
Very Negative
The cash flow statement reveals negative operating and free cash flow, which is a red flag for sustainability. The company heavily relies on financing activities to cover cash flow deficiencies, which is not sustainable long-term. The cash flow to net income ratios are unfavorable due to ongoing losses.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.00
EBITDA-8.14M-7.95M-8.63M-10.84M-11.93M-145.00K
Net Income-14.41M-15.04M-120.00K-10.83M-11.99M-1.63M
Balance Sheet
Total Assets3.97M6.62M12.21M5.50M2.04M4.62M
Cash, Cash Equivalents and Short-Term Investments3.70M6.50M11.99M5.25M1.27M4.49M
Total Debt0.000.000.000.0016.75K0.00
Total Liabilities1.09M1.91M5.56M4.45M2.14M1.21M
Stockholders Equity2.88M4.71B6.65M1.05M-99.47K3.41M
Cash Flow
Free Cash Flow-23.28M-18.34M-7.29M-11.22M-11.22M-215.07K
Operating Cash Flow-23.24M-18.32M-7.29M-11.22M-11.09M-215.07K
Investing Cash Flow-301.14K-19.17K0.000.00-131.96K-74.04M
Financing Cash Flow12.85M12.85M14.03M15.20M8.00M74.26M

Revelation Biosciences Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.76
Price Trends
50DMA
2.03
Negative
100DMA
2.74
Negative
200DMA
6.64
Negative
Market Momentum
MACD
-0.35
Negative
RSI
24.64
Positive
STOCH
37.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For REVB, the sentiment is Negative. The current price of 0.76 is below the 20-day moving average (MA) of 0.82, below the 50-day MA of 2.03, and below the 200-day MA of 6.64, indicating a bearish trend. The MACD of -0.35 indicates Negative momentum. The RSI at 24.64 is Positive, neither overbought nor oversold. The STOCH value of 37.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for REVB.

Revelation Biosciences Risk Analysis

Revelation Biosciences disclosed 62 risk factors in its most recent earnings report. Revelation Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Revelation Biosciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.41B0.36-61.88%2.33%17.09%1.64%
38
Underperform
$8.82M-1023.93%83.04%
32
Underperform
$5.31M-200.53%133.58%82.60%
28
Underperform
$1.54M-233.26%-115.81%
$3.82M-35.31%
24
Underperform
$3.06M-178.91%82.47%
$8.40M-89.46%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
REVB
Revelation Biosciences
0.76
-29.16
-97.46%
VIVS
VivoSim Labs
1.47
-7.64
-83.86%
APVO
Aptevo Therapeutics
3.08
-244.08
-98.75%
ENVB
Enveric Biosciences
1.24
-7.51
-85.83%
ENSC
Ensysce Biosciences
2.24
-5.26
-70.13%
SNPX
Synaptogenix
6.04
1.89
45.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 24, 2025